Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af ITI-1284 som en supplerende behandling hos patienter med generaliseret angstlidelse

2. november 2026 opdateret af: Intra-Cellular Therapies, Inc.

En multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til vurdering af effektiviteten, sikkerheden og tolerabiliteten af ​​ITI-1284 som en supplerende behandling hos patienter med generaliseret angst, som har en utilstrækkelig respons på behandling af generaliseret angst.

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

705

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Blagoevgrad, Bulgarien, 2700
        • Rekruttering
        • Medical Center Sv Dimitar Blagoevgrad
      • Burgas, Bulgarien, 8001
        • Rekruttering
        • Mental Health Center Prof. Dr. Ivan Temkov
      • Pleven, Bulgarien, 5800
        • Rekruttering
        • Outpatient care-group practice for specialized psychiatric care Datamed OOD
      • Plovdiv, Bulgarien, 4004
        • Rekruttering
        • Medical Center Mentalcare OOD
      • Rousse, Bulgarien, 7003
        • Rekruttering
        • Mental Health Center - Rousse
      • Sofia, Bulgarien, 1680
        • Rekruttering
        • Medical Center Intermedica, OOD
      • Sofia, Bulgarien, 1408
        • Rekruttering
        • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
      • Sofia, Bulgarien, 1510
        • Rekruttering
        • Medical Center Hera EOOD
      • Sofia, Bulgarien, 1113
        • Rekruttering
        • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
      • Targovishte, Bulgarien, 7700
        • Rekruttering
        • Medical center - VAS OOD
      • Varna, Bulgarien, 9020
        • Rekruttering
        • Diagnostic Consulting Center Mladost - M Varna
      • Varna, Bulgarien, 9020
        • Rekruttering
        • Diagnostic Consulting Center Mladost - M Varna 1
      • Vratsa, Bulgarien, 3000
        • Rekruttering
        • Mental Health Center - Vratsa EOOD
      • Kuopio, Finland, 70110
        • Rekruttering
        • Savon Psykiatripalvelu
      • Oulu, Finland, 90100
        • Rekruttering
        • Oulu Mentalcare Oy
      • Tampere, Finland, 33210
        • Rekruttering
        • Satakunnan Psykiatripalvelu Oy at Mehilainen Oy
    • California
      • Glendale, California, Forenede Stater, 91206
        • Rekruttering
        • Behavioral Research Specialists LLC
      • Imperial, California, Forenede Stater, 92251
        • Rekruttering
        • Sun Valley Research Center
      • Lemon Grove, California, Forenede Stater, 91945
        • Rekruttering
        • Synergy East
      • Oceanside, California, Forenede Stater, 92056
        • Rekruttering
        • Excell Research Inc
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • NRC Research Institute
      • Redlands, California, Forenede Stater, 92374
        • Rekruttering
        • Anderson Clinical Research
    • Florida
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • Miami Dade Medical Research Institute
      • Miami, Florida, Forenede Stater, 33122
        • Rekruttering
        • Premier Clinical Research
      • Miami, Florida, Forenede Stater, 33125
        • Rekruttering
        • Global Medical Institutes
      • Miami, Florida, Forenede Stater, 33186
        • Rekruttering
        • Sunshine Medical Solution
      • Miami Springs, Florida, Forenede Stater, 33166
        • Rekruttering
        • South Florida Research Inc
      • Tampa, Florida, Forenede Stater, 33634
        • Rekruttering
        • K2 Medical Research
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30331
        • Rekruttering
        • Atlanta Center for Medical Research
      • Atlanta, Georgia, Forenede Stater, 30030
        • Rekruttering
        • CenExeli Research LLC
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48105
        • Rekruttering
        • Michigan Clinical Research Institute
    • New Jersey
      • Toms River, New Jersey, Forenede Stater, 08755
        • Rekruttering
        • Bio Behavioral Health
    • New York
      • Brooklyn, New York, Forenede Stater, 11235
        • Rekruttering
        • SPRI Clinical Trials, LLC
    • Ohio
      • North Canton, Ohio, Forenede Stater, 44720
        • Rekruttering
        • Neuro Behavioral Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73120
        • Rekruttering
        • Sooner Clinical Research
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
        • Rekruttering
        • Lehigh Center for Clinical Research LLC
      • Media, Pennsylvania, Forenede Stater, 19063
        • Rekruttering
        • Suburban Research Associates
    • Texas
      • Austin, Texas, Forenede Stater, 78737
        • Rekruttering
        • Austin Clinical Trial Partners
      • Austin, Texas, Forenede Stater, 78759
        • Rekruttering
        • BioBehavioral Research of Austin PC
      • Plano, Texas, Forenede Stater, 75093
        • Rekruttering
        • Aims Trials LLC
    • Washington
      • Bellevue, Washington, Forenede Stater, 98007
        • Rekruttering
        • Northwest Clinical Research Center
      • Bialystok, Polen, 15-404
        • Rekruttering
        • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
      • Bydgoszcz, Polen, 85-080
        • Rekruttering
        • Przychodnia Srodmiescie SP. z o.o.
      • Gorlice, Polen, 38-300
        • Rekruttering
        • Specjalistyczna Praktyka Lekarska Piotr Zalitacz
      • Leszno, Polen, 64-100
        • Rekruttering
        • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
      • Poznan, Polen, 60 744
        • Rekruttering
        • Filip Rybakowski Specjalistyczna Praktyka Lekarska
      • Torun, Polen, 87 100
        • Rekruttering
        • Agnieszka Nowakowska Rudzka Gabinet Lekarski TCP Neuromed
      • Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Center of Serbia
      • Belgrade, Serbien, 11000
        • Rekruttering
        • Institute of Mental Health Serbia
      • Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Center of Serbia 1
      • Kovin, Serbien, 26220
        • Rekruttering
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac, Serbien, 34000
        • Rekruttering
        • University Clinical Center Kragujevac
      • Novi Kneževac, Serbien, 23330
        • Rekruttering
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Brno, Tjekkiet, 60200
        • Rekruttering
        • Medipa S R O
      • Pilsen, Tjekkiet, 301 00
        • Rekruttering
        • A Shine S R O
      • Prague, Tjekkiet, 10000
        • Rekruttering
        • Clintrial s r o
      • Prague, Tjekkiet, 16000
        • Rekruttering
        • Medical Services Prague S R O
      • Prague, Tjekkiet, 18600
        • Rekruttering
        • Institut Neuropsychiatricke pece

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Provide written informed consent before the initiation of any study specific procedures;

  2. Male or female patients ≥ 18 years of age;

  3. At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD (current GAD) as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:

    1. HAM-A Total score of ≥ 22;
    2. HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;
    3. CGI-S score of ≥ 4;
  4. History of inadequate response (< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire [ATRQ] for GAD) to at least 1 GAD-approved treatment (ie, one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) taken at an adequate dose (at least a minimum total daily dose of paroxetine 20 milligrams [mg], venlafaxine XR 75 mg, duloxetine 60 mg, escitalopram 10 mg, or buspirone 20 mg) and duration (ie, daily for at least 6 weeks) for the treatment of ongoing GAD symptoms;

  5. Currently having an inadequate response to one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75 mg, duloxetine 60 mg, escitalopram 10 mg, or buspirone 20 mg) and duration (ie, for at least 6 weeks prior to Screening) and agrees to continue the same dosing regimen for the duration of the study.

NOTE: The current GAD-approved treatment must be different from the GAD treatment identified as the historical failure.

Exclusion Criteria:

  1. Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:

    1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
    2. Bipolar Disorder;
  2. MADRS total score > 18 at Screening or Baseline;

  3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or

    1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
    2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;
    3. At Screening or Baseline MADRS Item 10 score ≥ 5; or
    4. The patient is considered to be an imminent danger to him/herself or others based on the assessment of the Investigator.
  4. Lifetime history of failure to respond to > 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75 mg, duloxetine 60 mg, escitalopram 10 mg, or buspirone 20 mg) and for an adequate duration (ie, at least 6 weeks).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Matching placebo tablet, taken once daily, sublingual administration

Eksperimentel: ITI-1284 10 mg

ITI-1284 10 mg tablet, taken once daily, sublingual administration.

Eksperimentel: ITI-1284 20 mg

ITI-1284 20 mg tablet, taken once daily, sublingual administration.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Week 6

The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It comprises of 14 items that are rated on a 5-point scale ranging from 0 = not present to 4 = very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 with a higher score indicating increased severity of anxiety symptoms.

Week 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Global Impression Scale-Severity (CGI-S)
Tidsramme: Week 6

The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients)

Week 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Intra-Cellular Therapies,Inc. Clinical Trial, Intra-Cellular Therapies, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. august 2024

Primær færdiggørelse (Anslået)

16. marts 2027

Studieafslutning (Anslået)

21. oktober 2027

Datoer for studieregistrering

Først indsendt

24. juni 2024

Først indsendt, der opfyldte QC-kriterier

24. juni 2024

Først opslået (Faktiske)

28. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ITI-1284-301
  • 2024-513302-56-00 (Registry Identifier: EUCT number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .